1. Albain K, Barlow W, O’Malley F et al. for the North American Intergroup (2004) Mature outcomes and new biologic correlates on phase III intergroup trial 0100 (INT 0100, SWOG-8814): Concurrent (CAFT) vs. sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) vs T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer. Proc San Antonio Breast Cancer Symposium 37 (Abstract)
2. Berry DA, Cirrincione C, Henderson IC et al. (2004) Effects of improvements in chemotherapy on disease-free and overall survival of estrogen-receptor negative, node-positive breast cancer: 20-year experience of the CALGB & U.S. Breast Intergroup. Proc San Antonio Breast Cancer Symposium 29 (Abstract)
3. Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304: 10–15
4. Bonadonna G, Valagussa, P, Moliterni A, Zambetti M et al. (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in nodepositive breast cancer. N Engl J Med 332: 901–906
5. Bonneterre J, Roche H, Kerbrat P, Bremond A et al. (2005) Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 23(12): 2686–2693